MONITORING AGENCY REPORT FOR THE QUARTER ENDED SEPTEMBER 30, 2026 IN RESPECT OF FUNDS RAISED THROUGH…
As filed · MONITORING AGENCY REPORT FOR THE QUARTER ENDED SEPTEMBER 30, 2026 IN RESPECT OF FUNDS RAISED THROUGH PREFERENTIAL ISSUE OF 2,60,00,000 FULLY CONVERTIBLE WARRANTS.
What happened
FactMONITORING AGENCY REPORT FOR THE QUARTER ENDED SEPTEMBER 30, 2026 IN RESPECT OF FUNDS RAISED THROUGH PREFERENTIAL ISSUE OF 2,60,00,000 FULLY CONVERTIBLE WARRANTS. 2026 IN RESPECT OF FUNDS RAISED THROUGH PREFERENTIAL ISSUE OF 2,60,00,000 FULLY. CONVERTIBLE WARRANTS.
Why it matters
CapitSignal interpretationShares are issued to named investors at a set price, diluting existing holders and changing who sits on the register.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Demand
DelayedIn the second quarter we are expecting a major push from Arrotex on that Macrogol new molecule which we launched.
And in third and fourth quarter we see a lot of progress coming from Ibuprofen and Clarithromycin granules.
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Who the allottees are
- Issue price versus market price
- Lock-in period on the new shares
- We expect FY27 to witness revenue growth of more than 50%. (management committed by FY27)
- A key milestone was the commercialization of the Viatris (USA), Manx (UK) and Arrotex (Australia) CDMO partner (management committed by FY27)
Evidence
- MONITORING AGENCY REPORT FOR THE QUARTER ENDED SEPTEMBER 30, 2026 IN RESPECT OF FUNDS RAISED THROUGH PREFERENTIAL ISSUE OF 2,60,00,000 FULLY CONVERTIBLE WARRANTS.(opens the original filing in a new tab)
- Earlier statement · Q1 FY27
- Latest statement · Q1 FY27
- Earlier statement · Q1 FY27
How CapitSignal classified this
- Reasoning:
- PREFERENTIAL_ALLOTMENT base 66; +4 corroborating keywords; +5 quantified amount; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%